加畑 馨 (カハタ カオル)

北海道大学病院 医療・ヘルスサイエンス研究開発機構講師

研究者基本情報

■ 学位
  • 医学博士, 北海道大学
■ URL
researchmap URLホームページURL■ ID 各種
研究者番号
  • 00399867
J-Global ID■ 研究キーワード・分野
研究キーワード
  • Regenerative medicine
  • Cell therapy
  • Oncology
  • Hematology
■ 担当教育組織

研究活動情報

■ 論文
  • VEXAS syndrome with cochleovestibular involvement.
    Keishi Fujiwara; Shinya Morita; Kimiko Hoshino; Hideaki Takeda; Kento Komatsuda; Kaoru Kahata; Yuji Nakamaru; Akihiro Homma
    Auris, nasus, larynx, 53, 1, 70, 75, 2025年12月18日, [国際誌]
    英語, 研究論文(学術雑誌), We report a case of VEXAS syndrome in a 71-year-old man presenting with auricular chondritis, scleritis, hearing loss, and vestibular dysfunction. Although the clinical picture initially suggested relapsing polychondritis, hematologic findings and UBA1 variant confirmed VEXAS syndrome. Comprehensive audiovestibular testing revealed bilateral sensorineural hearing loss and global vestibular impairment. Steroid therapy led to partial improvement. This case highlights the potential for inner ear involvement in VEXAS syndrome, underscoring the importance of systematic audiovestibular evaluation and clinical awareness to differentiate it from similar conditions such as relapsing polychondritis.
  • Safety and Efficacy of Graft-versus-Host Disease Prophylaxis with Mini-Dose Methotrexate in Umbilical Cord Blood Transplantation: An NJHSG-CBT18 Observational Study.
    Souichi Shiratori; Keito Suto; Yuta Hasegawa; Takahide Ara; Toshihiro Matsukawa; Hideki Goto; Masahiro Onozawa; Masao Nakagawa; Kaoru Kahata; Daisuke Hidaka; Reiki Ogasawara; Kohei Okada; Junichi Sugita; Yasutaka Kakinoki; Shuichi Ota; Daigo Hashimoto; Takanori Teshima
    Transplantation and cellular therapy, 2025年11月06日, [国際誌]
    英語, 研究論文(学術雑誌), Tacrolimus (Tac) and methotrexate (MTX) are standard graft-versus-host disease (GVHD) prophylaxis for umbilical cord blood transplantation (CBT); however, the optimal dose of MTX for CBT remains to be determined. We previously showed the safety and efficacy of reduced-dose MTX (mini-MTX; 5 mg/m2 on days 1, 3, and 6) combined with Tac as GVHD prophylaxis for CBT in a single-center retrospective study. Here we report a multicenter observational study in the North Japan Hematology Study Group (NJHSG; NJHSG-CBT18) conducted to evaluate transplantation outcomes according to GVHD prophylaxis in single-unit CBT, in which patients with hematologic malignancies scheduled for CBT were prospectively registered and followed for 2 years after CBT. A total of 112 patients were registered in NJHSG-CBT18, with a median age of 51 years. Eighty-nine patients received Tac + mini-MTX, 19 patients received Tac + mycophenolate mofetil (MMF), and 4 patients received Tac only as GVHD prophylaxis. Multivariate analysis identified GVHD prophylaxis other than Tac + mini-MTX as a significant risk factor for nonrelapse mortality (NRM) (hazard ratio [HR], 0.160; 95% confidence interval [CI], 0.065 to 0.391; P < .001), overall survival (OS) (HR, 2.971; 95% CI, 1.558 to 5.663; P < .001), progression-free survival (PFS) (HR, 2.383; 95% CI, 1.345 to 4.222; P = .003), and GVHD-free, relapse-free survival (GRFS) (HR, 3.075; 95% CI, 1.799 to 5.256; P < .001). In a comparison of clinical outcomes between the mini-MTX and MMF groups, the cumulative incidences of pre-engraftment immune reaction (5.7% versus 42.1%; P < .001), human herpesvirus 6 encephalitis (2.3% versus 15.8%, P = .011), grade II-IV acute GVHD (14.6% versus 47.4%, P < .001), and NRM (1.1% versus 52.6%, P < .001) were significantly lower and the cumulative incidence of immunosuppressant discontinuation was significantly higher (66.3% versus 18.4%, P = .004) in the mini-MTX group compared to the MMF group, while rates of chronic GVHD and relapse were comparable between the groups. The probabilities of OS (70.6% versus 31.6%, P < .001), PFS (58.1 versus 14.0%, P < .001), and GRFS (44.9% versus 5.1%, P < .001) were significantly higher in the mini-MTX group. Multivariate analysis of risk factors for OS in the mini-MTX group identified high-risk or very high-risk refined Disease Risk Index (rDRI) (HR, 3.896; 95% CI, 1.575 to 9.637; P = .003) and high HCT-CI (HR, 3.338; 95% CI, 1.301 to 8.569; P = .012) as significant risk factors for OS. Our data indicate that a combination of Tac + mini-MTX is safe and effective GVHD prophylaxis in CBT.
  • Phase I/II trial of intracerebral transplantation of autologous bone marrow stem cells combined with recombinant peptide scaffold for patients with chronic intracerebral haemorrhage: a study protocol.
    Masahito Kawabori; Hideo Shichinohe; Kaoru Kahata; Arisa Miura; Kenichiro Maeda; Yoichi M Ito; Masahiko Mukaino; Ryo Kogawa; Kentaro Nakamura; Shuho Gotoh; Kota Kurisu; Miki Fujimura
    BMJ open, 14, 12, e083959, 2024年12月02日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), INTRODUCTION: Intracerebral haemorrhage (ICH) stands as a leading global cause of death and disability, posing a significant challenge with limited treatment options, especially for chronic patients. Recent advances in stem cell therapies have opened new avenues for therapeutic potential. Our previous preclinical research has demonstrated that intracerebral transplantation of bone marrow stromal cells (BMSCs) combined with a recombinant human collagen type I scaffold enables higher cell survival and engraftment and holds promising potential. In this article, we present the protocol for a novel clinical trial, named 'Research on Advanced Intervention using Novel Bone MarrOW stem cells for chronic intracerebral haemorrhage' (RAINBOW-Hx). METHODS AND ANALYSIS: RAINBOW-Hx is a phase I/II, open-label, uncontrolled study with the primary objective of assessing the safety and efficacy of intracerebral transplantation of autologous BMSCs combined with the scaffold (HUFF-01) in patients with chronic ICH. Eight patients, experiencing moderate to severe neurological deficits for 12 months or longer, will be enrolled. The haemorrhage location will be limited to the basal ganglia and thalamus. Approximately 50 mL of bone marrow will be extracted from the iliac bone of each patient, and BMSCs will be cultured using autologous platelet lysate. 3 days before transplantation, BMSCs will be combined with the scaffold to generate HUFF-01. Each patient will receive a 50 000 HUFF-01 dose, containing approximately 50 million BMSCs, through stereotactic transplantation into the haemorrhagic cavity. Neurological assessments, MRI, 18F-fluorodeoxyglucose positron emission tomography and 123I-Iomazenil single-photon emission CT will be performed for 1 year after administration. ETHICS AND DISSEMINATION: The trial protocols were reviewed and approved by the Institutional Review Board of the Hokkaido University Hospital (R5-11), and this study is conducted according to Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. The results of this trial will be submitted for publication in a peer-reviewed scientific journal. TRIAL REGISTRATION NUMBER: jRCT2013230053, Japan Registry of Clinical Trials.
  • Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR-T cell manufacturing failure in myeloma
    Tomoyasu Jo; Kyoko Yoshihara; Masaki Ri; Nobuhiro Tsukada; Naoya Mimura; Keiko Fujii; Kentaro Fukushima; Shin-ichiro Fujiwara; Yuji Shimura; Kyoko Haraguchi; Koji Kato; Atsushi Satake; Akiyo Yoshida; Rikio Suzuki; Junko Ikemoto; Keita Iwaki; Wataru Takeda; Noboru Yonetani; Ryuji Tanosaki; Minami Yamada-Fujiwara; Kaoru Kahata; Tokiko Nagamura-Inoue; Satoshi Yoshihara; Yasuyuki Arai
    Blood Neoplasia, 2, 1, 100051, 100051, Elsevier BV, 2024年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy has significantly improved management of relapsed or refractory multiple myeloma. However, manufacturing failure due to poor cell growth necessitates revision of treatment strategies that negatively impact patients. To identify risk factors for CAR-T manufacturing failure in patients with myeloma, a nationwide cohort study was performed, analyzing patients who underwent apheresis for idecabtagene vicleucel in Japan. Of 154 patients analyzed, 13 cases (8.4%) experienced manufacturing failure. We compared clinical factors between patients with manufacturing failure (failed group) and those who met specifications (successful group). Patients in the failed group had a higher prevalence of deletion 17p at diagnosis (38.5% vs 14.9%), were more likely to have been treated with alkylating agents within 6 months before apheresis (53.8% vs 23.4%), and had undergone more chemotherapy lines before apheresis (median, 6 vs 5). Additionally, patients with manufacturing failure exhibited significantly lower hemoglobin levels (8.6 vs 10.0 g/dL), platelet counts (5.9 × 104/μL vs 13.8 × 104/μL), and CD4/CD8 ratios (0.169 vs 0.474) than patient with successful manufacturing. Multivariate analysis revealed that low platelet counts (odds ratio [OR], 0.130 for every increase of 105/μL; P = .041), or low CD4/CD8 ratios (OR, 0.100 for each doubling; P = .003) at apheresis increased the risk of manufacturing failure. Alkylating agents within 6 months before apheresis were associated with decreased platelet counts and CD4/CD8 ratios. Manufacturing failure remains an obstacle to CAR-T therapy for patients with myeloma. Avoiding risk factors, such as alkylating agents, and adopting risk-adapted strategies may optimize CAR-T therapy for patients with myeloma.
  • Intracerebral transplantation of MRI-trackable autologous bone marrow stromal cells for patients with subacute ischemic stroke.
    Masahito Kawabori; Satoshi Kuroda; Hideo Shichinohe; Kaoru Kahata; Souichi Shiratori; Satoshi Ikeda; Taisuke Harada; Kenji Hirata; Khin Khin Tha; Masato Aragaki; Shunsuke Terasaka; Yoichi M Ito; Naoki Nishimoto; Shunsuke Ohnishi; Ichiro Yabe; Kohsuke Kudo; Kiyohiro Houkin; Miki Fujimura
    Med (New York, N.Y.), 5, 5, 432, 444, 2024年03月18日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Ischemic stroke is one of the leading causes of death and neurological disability worldwide, and stem cell therapy is highly expected to reverse the sequelae. This phase 1/2, first-in-human study evaluated the safety, feasibility, and monitoring of an intracerebral-transplanted magnetic resonance imaging (MRI)-trackable autologous bone marrow stromal cell (HUNS001-01) for patients with subacute ischemic stroke. METHODS: The study included adults with severe disability due to ischemic stroke. HUNS001-01 cultured with human platelet lysates and labeled with superparamagnetic iron oxide was stereotactically transplanted into the peri-infarct area 47-64 days after ischemic stroke onset (dose: 2 or 5 × 107 cells). Neurological and radiographic evaluations were performed throughout 1 year after cell transplantation. The trial was registered at UMIN Clinical Trial Registry (number UMIN000026130). FINDINGS: All seven patients who met the inclusion criteria successfully achieved cell expansion, underwent intracerebral transplantation, and completed 1 year of follow-up. No product-related adverse events were observed. The median National Institutes of Health Stroke Scale and modified Rankin scale scores before transplantation were 13 and 4, which showed improvements of 1-8 and 0-2, respectively. Cell tracking proved that the engrafted cells migrated toward the infarction border area 1-6 months after transplantation, and the quantitative susceptibility mapping revealed that cell signals at the migrated area constantly increased throughout the follow-up period up to 34% of that of the initial transplanted site. CONCLUSIONS: Intracerebral transplantation of HUNS001-01 was safe and well tolerated. Cell tracking shed light on the therapeutic mechanisms of intracerebral transplantation. FUNDING: This work was supported by the Japan Agency for Medical Research and Development (AMED; JP17bk0104045 and JP20bk0104011).
  • Incidence and course of Epstein-Barr virus viremia after allogeneic hematopoietic stem cell transplant for adult-onset systemic chronic active Epstein-Barr virus disease.
    Preeti Prerna M Vaswani; Masahiro Onozawa; Yuta Hasegawa; Hiroyuki Ohigashi; Takahide Ara; Toshihiro Matsukawa; Atsushi Yasumoto; Souichi Shiratori; Hideki Goto; Masao Nakagawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
    Bone marrow transplantation, 58, 12, 1397, 1399, 2023年09月05日, [査読有り], [国際誌]
    英語
  • Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan.
    Tomoyasu Jo; Satoshi Yoshihara; Yoshiki Okuyama; Keiko Fujii; Tomoko Henzan; Kaoru Kahata; Rie Yamazaki; Wataru Takeda; Yoshihiro Umezawa; Kentaro Fukushima; Takashi Ashida; Minami Yamada-Fujiwara; Ryo Hanajiri; Noboru Yonetani; Yuma Tada; Yuji Shimura; Hidekazu Nishikii; Norio Shiba; Naoya Mimura; Jun Ando; Takayuki Sato; Yasuhiro Nakashima; Junko Ikemoto; Keita Iwaki; Shin-Ichiro Fujiwara; Masaki Ri; Tokiko Nagamura-Inoue; Ryuji Tanosaki; Yasuyuki Arai
    British journal of haematology, 202, 2, 256, 266, 2023年04月25日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), For successful chimeric antigen receptor T (CAR-T) cell therapy, CAR-T cells must be manufactured without failure caused by suboptimal expansion. In order to determine risk factors for CAR-T cell manufacturing failure, we performed a nationwide cohort study in Japan and analysed patients with diffuse large B-cell lymphoma (DLBCL) who underwent tisagenlecleucel production. We compared clinical factors between 30 cases that failed (7.4%) with those that succeeded (n = 378). Among the failures, the proportion of patients previously treated with bendamustine (43.3% vs. 14.8%; p < 0.001) was significantly higher, and their platelet counts (12.0 vs. 17.0 × 104 /μL; p = 0.01) and CD4/CD8 T-cell ratio (0.30 vs. 0.56; p < 0.01) in peripheral blood at apheresis were significantly lower than in the successful group. Multivariate analysis revealed that repeated bendamustine use with short washout periods prior to apheresis (odds ratio [OR], 5.52; p = 0.013 for ≥6 cycles with washout period of 3-24 months; OR, 57.09; p = 0.005 for ≥3 cycles with washout period of <3 months), low platelet counts (OR, 0.495 per 105 /μL; p = 0.022) or low CD4/CD8 ratios (
  • びまん性大細胞型B細胞リンパ腫に対するCAR-T細胞製造失敗のリスク因子の解析
    城 友泰; 新井 康之; 吉原 哲; 武田 航; 池本 純子; 岩木 啓太; 米谷 昇; 藤原 慎一郎; 李 政樹; 加畑 馨; 長村 登紀子; 藤原 実名美; 田野崎 隆二
    日本輸血細胞治療学会誌, 69, 2, 330, 330, (一社)日本輸血・細胞治療学会, 2023年04月
    日本語
  • Protocol for treating lumbar spinal canal stenosis with a combination of ultrapurified, allogenic bone marrow-derived mesenchymal stem cells and in situ-forming gel: a multicentre, prospective, double-blind randomised controlled trial.
    Hideki Sudo; Takashi Miyakoshi; Yudai Watanabe; Yoichi M Ito; Kaoru Kahata; Khin Khin Tha; Nozomi Yokota; Hiroe Kato; Tomoko Terada; Norimasa Iwasaki; Teruyo Arato; Norihiro Sato; Toshiyuki Isoe
    BMJ open, 13, 2, e065476, 2023年02月02日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), INTRODUCTION: In patients with combined lumbar spinal canal stenosis (LSCS), a herniated intervertebral disc (IVD) that compresses the dura mater and nerve roots is surgically treated with discectomy after laminoplasty. However, defects in the IVD after discectomy may lead to inadequate tissue healing and predispose patients to the development of IVD degeneration. Ultrapurified stem cells (rapidly expanding clones (RECs)), combined with an in situ-forming bioresorbable gel (dMD-001), have been developed to fill IVD defects and prevent IVD degeneration after discectomy. We aim to investigate the safety and efficacy of a new treatment method in which a combination of REC and dMD-001 is implanted into the IVD of patients with combined LSCS. METHODS AND ANALYSIS: This is a multicentre, prospective, double-blind randomised controlled trial. Forty-five participants aged 20-75 years diagnosed with combined LSCS will be assessed for eligibility. After performing laminoplasty and discectomy, participants will be randomised 1:1:1 into the combination of REC and dMD-001 (REC-dMD-001) group, the dMD-001 group or the laminoplasty and discectomy alone (control) group. The primary outcomes of the trial will be the safety and effectiveness of the procedure. The effectiveness will be assessed using visual analogue scale scores of back pain and leg pain as well as MRI-based estimations of morphological and compositional quality of the IVD tissue. Secondary outcomes will include self-assessed clinical scores and other MRI-based estimations of compositional quality of the IVD tissue. All evaluations will be performed at baseline and at 1, 4, 12, 24 and 48 weeks after surgery. ETHICS AND DISSEMINATION: This study was approved by the ethics committees of the institutions involved. We plan to conduct dissemination of the outcome data by presenting our data at national and international conferences, as well as through formal publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: jRCT2013210076.
  • [Manufacturing results of tisagenlecleucel for acute lymphoblastic leukemia: a survey by the CAR-T cell therapy taskforce of the Japan Society of Transfusion Medicine and Cell Therapy].
    Tomoyasu Jo; Tomoko Henzan; Daisuke Tomizawa; Satoru Yoshihara; Kaoru Kahata; Minami Yamada-Fujiwara; Yoshiki Okuyama; Norio Shiba; Keiko Fujii; Yoshihiro Umezawa; Rie Yamazaki; Wataru Takeda; Ryo Hanajiri; Kentaro Fukushima; Naoya Mimura; Junko Ikemoto; Keita Iwaki; Noboru Yonetani; Shin-Ichiro Fujiwara; Masaki Ri; Tokiko Nagamura-Inoue; Ryuji Tanosaki; Yasuyuki Arai
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 64, 5, 331, 337, 2023年, [国内誌]
    日本語, 研究論文(学術雑誌), The frequency of the manufacturing failure of chimeric antigen receptor (CAR)-T cell therapy in clinical practice is unknown. To clarify the current state of how likely CAR-T cell production is to succeed or fail for B-cell acute lymphoblastic leukemia (B-ALL), we analyzed cases in which the production of tisagenlecleucel was performed for patients with B-ALL at 15 facilities in Japan from October 2019 to March 2022. Total 81 patients (47 males and 34 females) were analyzed. The median age at apheresis was 13 years (1-25) with a median number of prior treatments of 4 (1-9). The numbers of patients with histories of allogeneic transplantation, inotuzumab ozogamicin, or blinatumomab treatments were 51 (63.0%), 26 (32.1%), and 37 (45.7%), respectively. The median blast percentage and CD3+ cell counts in peripheral blood were 0% (0-91.5), and 611/µl (35-4,210) at apheresis, and the median number of CD3+ cells shipped was 2.2×109 (0.5-8.3). While cases with a history of heavy prior treatment before apheresis were included, no manufacturing failures were observed. Continuing to monitor the status of manufacturing failures is necessary as the number of B-ALL cases treated with CAR-T cell therapy increases.
  • 今月の特集 移植医療と臨床検査 造血幹細胞移植と臨床検査
    安本 篤史; 加畑 馨; 豊嶋 崇徳
    臨床検査, 65, 12, 1310, 1316, 株式会社医学書院, 2021年12月15日
    日本語
  • High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease
    Souichi Shiratori; Hiroyuki Ohigashi; Takahide Ara; Atsushi Yasumoto; Hideki Goto; Masao Nakagawa; Junichi Sugita; Masahiro Onozawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
    Annals of Hematology, 100, 5, 1321, 1328, Springer Science and Business Media LLC, 2021年05月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Antithymocyte globulin (ATG) reduces severe acute and chronic graft-versus-host disease (GVHD) in allogeneic peripheral blood stem cell transplantation (PBSCT). However, risk factors for severe acute GVHD in PBSCT using ATG remain to be determined. We conducted a single-center, retrospective study to analyze the association of acute GVHD requiring systemic corticosteroid (SC-aGVHD) with absolute lymphocyte counts (ALC) before the administration of ATG or conditioning in 53 patients with HLA-matched PBSCT using low-dose thymoglobulin (2 mg/kg) after myeloablative conditioning. The cumulative incidence of SC-aGVHD was 17.0% and ALC before ATG were significantly higher in patients with SC-aGVHD compared to that in patients without it (median, 0.15 × 109/L vs 0.06 × 109/L, P = 0.047). The cumulative incidence of SC-aGVHD was significantly higher in patients with high ALC before ATG (≥ 0.15 × 109/L) than in those with low ALC (38.5% vs 10.0%, P = 0.016). Non-relapse mortality (NRM) was also significantly higher in the high ALC before ATG group than the low ALC before ATG group (2-year NRM: 23.9% vs 6.0%, P = 0.048), leading to worse survival (2-year overall survival: 69.2% vs 83.5%, P = 0.039). Our study suggested that high ALC before ATG is a risk factor for SC-aGVHD.
  • [Emergence of mutation in the colony-stimulating factor 3 receptor gene during follow-up of unclassifiable myeloproliferative neoplasm].
    Shinpei Harada; Kohei Okada; Shota Yokoyama; Daisuke Hidaka; Eiko Hayase; Masahiro Onozawa; Hideki Goto; Daigo Hashimoto; Kaoru Kahata; Tomoyuki Endo; Takanori Teshima
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 62, 11, 1609, 1614, 2021年, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), A 25-year-old male with a medical history of stress polycythemia was admitted to a previous hospital for leukocytosis, anemia, and thrombocytopenia. Bone marrow examination revealed left-shifted myeloid hyperplasia without increased blasts and normal male karyotype. No mutations of JAK2, V617F, and colony-stimulating factor 3 receptor gene (CSF3R) were detected. Fluorescence in-situ hybridization for BCR-ABL1 and FIP1L1-PDGFRA were negative. Based on these findings, a diagnosis of an unclassifiable myeloproliferative neoplasm was made, and he was started on hydroxyurea treatment. He was referred to our hospital in April 2016 for transfusion dependence. Bone marrow examination performed at our hospital revealed granulocytic dysplasia and CSF3R T618I was detected. After induction therapy, CSF3R T618I became undetectable, and he went on to undergo allogeneic stem cell transplantation in October 2016. He has been in remission for >4 years posttransplantation. CSF3R T618I is one of the genes responsible for chronic neutrophilic leukemia and atypical chronic myeloid leukemia, suggesting its involvement in the pathogenesis of this case.
  • 再生医療等製品の不均一性と品質管理
    加畑 馨
    Pharm stage, 20, 8, 42, 45, 技術情報協会, 2020年11月, [招待有り], [筆頭著者], [国内誌]
    日本語, 研究論文(学術雑誌)
  • Feasibility and efficacy of low-dose pegfilgrastim for CD34+ cell mobilization in lymphoma.
    Hideki Goto; Daisuke Hidaka; Satoshi Yamamoto; Koji Hayasaka; Rie Michimata; Ikuko Kagawa; Kana Sunagoya; Hiroaki Iijima; Eiko Hayase; Souichi Shiratori; Kohei Okada; Junichi Sugita; Masahiro Onozawa; Daigo Hashimoto; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Chikara Shimizu; Takanori Teshima
    Journal of clinical apheresis, 35, 5, 413, 419, 2020年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Pegfilgrastim has equivalent efficacy to daily granulocyte colony-stimulating factor (G-CSF) in enhancing neutrophil recovery after chemotherapy, but data on its use for peripheral blood stem cell (PBSC) mobilization are limited. We evaluated the safety and efficacy of CD34+ PBSC mobilization by low-dose (3.6 mg) pegfilgrastim after chemotherapy in patients with malignant lymphoma. STUDY DESIGN AND METHODS: Twenty patients with malignant lymphoma were enrolled in this study. Cytotoxic chemotherapy was started on day 1, and 3.6 mg of pegfilgrastim was subcutaneously administered on day 7. CD34+ cells were counted in the peripheral blood daily from days 11 to 14 using a flow cytometric analysis. RESULTS: In 19 of the 20 patients (95%), the CD34+ cell counts in the peripheral blood exceeded 10 × 106/L, with a mean value of 20.3 on day 11, 38.0 on day 12, 40.3 on day 13, and 40.1 on day 14. Older age was associated with lower maximum CD34+ cell mobilization. The most frequent adverse events associated with pegfilgrastim were back pain, nausea, appetite loss, and lactate dehydrogenase elevation. CONCLUSION: Our data indicated that a single dose of 3.6 mg pegfilgrastim on day 7 after chemotherapy safely and effectively mobilized CD34+ cells.
  • Reduced dose of MTX for GVHD prophylaxis promotes engraftment and decreases non-relapse mortality in umbilical cord blood transplantation.
    Souichi Shiratori; Hiroyuki Ohigashi; Shuichiro Takahashi; Takahide Ara; Hideki Goto; Masao Nakagawa; Junichi Sugita; Masahiro Onozawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
    Annals of hematology, 99, 3, 591, 598, 2020年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Although a combination of calcineurin inhibitor and methotrexate (MTX) is used for graft-versus-host disease (GVHD) prophylaxis in umbilical cord blood transplantation (CBT), optimal dose of MTX for CBT remains to be determined.We conducted a retrospective study to evaluate the safety and efficacy of standard-dose MTX (St-MTX, 15 mg/m2 on day 1 and 10 mg/m2 on days 3 and 6) and mini-dose MTX (Mini-MTX, 5 mg/m2 on days 1, 3 and 6) for GVHD prophylaxis in patients who underwent single unit CBT against hematological malignancies.Thirty-two and 26 patients received St-MTX and Mini-MTX, respectively. Cumulative incidence of neutrophil engraftment was significantly higher in the Mini-MTX group than in the St-MTX group (88.5% vs 65.6%, P = 0.00448). Cumulative incidences of grade II to IV and grade III to IV of acute graft-versus-host disease (GVHD) were 34.4% and 6.2% in the St-MTX group, and 34.6% and 7.7% in the Mini-MTX group with no statistical significance. One-year non-relapse mortality (NRM) was significantly lower in the Mini-MTX group compared to the St-MTX group (31.2% vs 3.8%, P = 0.00938), whereas relapse rate was not different between the groups. Multivariate analysis also indicated that Mini-MTX significantly improved engraftment (HR, 0.5359; 95% CI, 0.3082 to 0.9318; P = 0.0270) and reduced NRM (HR, 0.117; 95% CI, 0.0151 to 0.9067; P = 0.040).Our study suggests that GVHD prophylaxis using Mini-MTX in CBT is feasible and associated with improvement of engraftment and reduction in NRM.
  • Extracorporeal Photopheresisの現状と展望
    加畑 馨
    日本アフェレシス学会雑誌, 39, 1, 24, 27, (一社)日本アフェレシス学会, 2020年02月, [招待有り], [筆頭著者], [国内誌]
    日本語, Extracorporeal photopheresis(ECP:体外循環式光療法)は、その治療原理や効果から、体外循環式光化学療法や体外循環式光免疫療法とも呼ばれる。ECPの作用機序、実施方法、適応疾患、副作用について概説した。日本では、インライン方式のECPがステロイド抵抗性の難治性慢性移植片対宿主病の治療法として保険承認される見通しである。今後、様々な病態への応用が期待される。
  • Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.
    Takashi Ikeda; Keita Mori; Koji Kawamura; Takehiko Mori; Shotaro Hagiwara; Yasunori Ueda; Kaoru Kahata; Naoyuki Uchida; Nobuhiro Tsukada; Satoshi Murakami; Masahide Yamamoto; Tsutomu Takahashi; Tatsuo Ichinohe; Makoto Onizuka; Yoshiko Atsuta; Yoshinobu Kanda; Shinichiro Okamoto; Kazutaka Sunami; Hiroyuki Takamatsu
    Hematological oncology, 37, 5, 586, 594, 2019年12月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Allogeneic stem cell transplantation (allo-SCT) offers a clinical option to young patients with multiple myeloma (MM) relapsing/progressing after autologous SCT (ASCT); however, this claim remains debatable. Thus, in this retrospective study, we analyzed 526 patients with MM who underwent SCT for MM relapsing/progressing after the prior ASCT using the registry data of the Japan Society for Hematopoietic Cell Transplantation (2001-2015) and compared overall survival (OS) between allo-SCT (n = 192) and autologous stem cell retransplantation groups (ReASCT; n = 334) based on risk factor points. Significant adverse factors for OS in all patients were (1) male sex, (2) less than partial response to SCT, (3) performance status of 2 to 4, and (4) short duration from the prior ASCT. We scored factor 2 as 1 point, factor 3 as 2 points, and factor 4 as 0, 1, or 2 points for more than 30, 9 to 30, or less than 9 months, respectively. We categorized patients into three risk subgroups based on their total points (0, 1-3, and 4-5 points), indicating the usefulness of this scoring system for prognosis prediction and treatment selection. Subgroup comparison revealed OS after ReASCT to be higher than that after allo-SCT in the intermediate-risk subgroup comprising the largest population (28.2% vs 21.5%, P < .004). We observed no significant advantages of allo-SCT over ReASCT in the low- and high-risk subgroups. These findings suggest that ReASCT is more advantageous than allo-SCT in many patients with MM relapsing/progressing after the prior ASCT. However, long-term survival patients were noted only in the allo-SCT group, and allo-SCT could exhibit clinical efficacy, particularly in the low-risk group. While further examination is warranted, allo-SCT could be a potential tool for a specific population with MM relapsing/progressing after the prior ASCT.
  • 骨髄異形成症候群の理解のために 分類と予後因子のup-to-date
    加畑 馨
    日本検査血液学会雑誌, 20, 2, 308, 314, (一社)日本検査血液学会, 2019年07月, [招待有り], [筆頭著者], [国内誌]
    日本語, 研究論文(学術雑誌)
  • I&A輸血機能評価認定の効果と課題
    渡邊 千秋; 加畑 馨; 早瀬 英子; 伊藤 誠; 上床 貴代; 魚住 諒; 林 泰弘; 秋沢 宏次; 清水 力
    日本輸血細胞治療学会誌, 65, 3, 645, 645, (一社)日本輸血・細胞治療学会, 2019年06月
    日本語
  • The association between the incidence of intestinal graft-vs-host disease and antibiotic use after allogeneic hematopoietic stem cell transplantation.
    Hidaka D; Hayase E; Shiratori S; Hasegawa Y; Ishio T; Tateno T; Okada K; Goto H; Sugita J; Onozawa M; Nakagawa M; Kahata K; Endo T; Hashimoto D; Teshima T
    Clinical transplantation, 32, 9, e13361, 2018年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Intestinal microbiota plays an important role in the regulation of allogeneic immune reaction after allogeneic hematopoietic stem cell transplantation (allo-SCT). Intestinal graft-vs-host disease (GVHD) is one of the major causes of mortality after allo-SCT and often complicated with intestinal dysbiosis. Recent studies suggest that antibiotic-induced dysbiosis is a risk factor for intestinal GVHD. We retrospectively evaluated the impacts of antibiotic use on the incidence of intestinal GVHD occurring before day 100 after allo-SCT. Among 213 patients who underwent allo-SCT, 200 patients achieving engraftment were analyzed. Antibiotics were classified into carbapenem, quinolone, penicillin, cephem, and glycopeptide. Among 128 patients who developed acute GVHD, intestinal GVHD developed in 36 patients. Patients with intestinal GVHD received significantly longer administration of carbapenem and glycopeptide compared to those without it in periengraftment period. In multivariate analysis, use of carbapenem for greater than 7 days was associated with an increased risk of intestinal GVHD. However, use of antibiotics for greater than 7 days was not associated with poor overall survival and high nonrelapse mortality. Long use of carbapenem in periengraftment period may be a risk for intestinal GVHD. Prospective studies are required to validate our findings.
  • Development of a Fluorescence in Situ Hybridization Probe for Detecting IKZF1 Deletion Mutations in Patients with Acute Lymphoblastic Leukemia
    Junichi Hashiguchi; Masahiro Onozawa; Satoshi Oguri; Shinichi Fujisawa; Masahisa Tsuji; Kohei Okada; Masao Nakagawa; Daigo Hashimoto; Kaoru Kahata; Takeshi Kondo; Chikara Shimizu; Takanori Teshima
    Journal of Molecular Diagnostics, 20, 4, 446, 454, Elsevier B.V., 2018年07月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study.
    Hidaka D; Onozawa M; Hashiguchi J; Miyashita N; Kasahara K; Fujisawa S; Hayase E; Okada K; Shiratori S; Goto H; Sugita J; Nakagawa M; Hashimoto D; Kahata K; Endo T; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Imai K; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Shimizu C; Kondo T; Teshima T
    Clinical lymphoma, myeloma & leukemia, 18, 11, e469-e479, 2018年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The prognostic effect of Wilms tumor 1 (WT1) expression at the diagnosis of acute myelogenous leukemia (AML) has been controversial. The aim of the present study was to determine the correlations of WT1 expression at the diagnosis of AML with established prognostic alterations. PATIENTS AND METHODS: We analyzed diagnostic bone marrow samples from 252 patients. WT1 expression, single nucleotide polymorphism (SNP) in the WT1 gene (rs16754), and Fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation were analyzed for all patients. The nucleophosmin 1 (NPM1) mutation and CCAAT/enhancer-binding protein-α (CEBPA) double mutation were analyzed for cytogenetically normal (CN)-AML. The KIT mutation was analyzed for core-binding factor AML. RESULTS: Within the cytogenetically favorable prognosis group, WT1 expression in AML with inv(16) or t(15;17) was significantly greater than that in AML with t(8;21). In cases with CN-AML, FLT3-ITD and NPM1 mutations both correlated with greater expression of WT1, and the CEBPA double mutation was related to lower WT1 expression. The existence of both FLT3-ITD and NPM1 mutations showed synergistically greater expression of WT1 in CN-AML. SNP in the WT1 gene (rs16754) was significantly associated with lower expression of WT1. The WT1 levels were not prognostic factors in the total cohort or any cytogenetic group or stratified by SNP status. CONCLUSION: Because WT1 expression has correlated with known prognostic factors, the prognostic effect of WT1 levels could be misunderstood depending on the distribution of the collaborative mutations in each cohort. We have concluded that the prognostic significance of WT1 at the diagnosis of AML is weak compared with the other established prognostic factors.
  • Extracorporeal photopheresis with TC-V in Japanese patients with steroid-resistant chronic graft-versus-host disease
    Shinichiro Okamoto; Takanori Teshima; Mizuha Kosugi-Kanaya; Kaoru Kahata; Naomi Kawashima; Jun Kato; Takehiko Mori; Yukiyasu Ozawa; Koichi Miyamura
    International Journal of Hematology, 108, 3, 1, 8, Springer Tokyo, 2018年06月29日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in Japan
    Chika Kawajiri-Manako; Emiko Sakaida; Chikako Ohwada; Toshihiro Miyamoto; Taichi Azuma; Jun Taguchi; Takehiko Mori; Yuichi Hasegawa; Tadakazu Kondo; Toshiaki Yujiri; Makoto Yoshimitsu; Kazunori Imada; Shingo Kurahashi; Kaoru Kahata; Tatsuo Ichinohe; Makoto Hirokawa; Yoshiko Atsuta; Chiaki Nakaseko
    Biology of Blood and Marrow Transplantation, 24, 6, 1180, 1186, Elsevier Inc., 2018年06月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Hematogones Predict Better Outcome in Allogeneic Hematopoietic Stem Cell Transplantation Irrespective of Graft Sources.
    Ishio T; Sugita J; Tateno T; Hidaka D; Hayase E; Shiratori S; Okada K; Goto H; Onozawa M; Nakagawa M; Hashimoto D; Kahata K; Fujimoto K; Endo T; Kondo T; Teshima T
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 24, 10, 1990, 1996, Elsevier BV, 2018年06月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Benign precursors of B lymphocytes, termed hematogones, are observed in the regenerative state of hematopoiesis following chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT). Previous studies have demonstrated that expansion of hematogones correlates with better clinical outcomes after allo-HSCT. We retrospectively analyzed the association between hematogones and clinical outcomes in 309 consecutive patients who underwent allo-HSCT, which is the largest population-based cohort reported so far. The incidence of hematogones was significantly higher in complete remission (CR) patients at the time of transplantation than in non-CR patients, after myeloablative conditioning than after reduced-intensity conditioning, with tacrolimus-based graft-versus-host disease (GVHD) prophylaxis than with cyclosporine-based prophylaxis, and with disease other than malignant lymphoma (all P < .05). Patients with hematogones developed less acute GVHD and infections than did those without them (P < .05). Emergence of hematogones was associated with superior GVHD-free relapse-free survival and lower nonrelapse mortality, and was an independent prognostic factor for overall survival, irrespective of donor sources.
  • A novel heterozygous ITGB3 p.T720del inducing spontaneous activation of integrin αIIbβ3 in autosomal dominant macrothrombocytopenia with aggregation dysfunction.
    Miyashita N; Onozawa M; Hayasaka K; Yamada T; Migita O; Hata K; Okada K; Goto H; Nakagawa M; Hashimoto D; Kahata K; Kondo T; Kunishima S; Teshima T
    Annals of hematology, 97, 4, 629, 640, Springer Verlag, 2018年04月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • 脳死肝移植時のフィブリノゲン製剤使用による術中出血量と輸血使用量に関する検討
    上床 貴代; 後藤 了一; 渡邊 千秋; 秋沢 宏次; 嶋村 剛; 清水 力; 豊嶋 崇徳; 早瀬 英子; 加畑 馨; 橋本 大吾; 伊藤 誠; 魚住 諒; 林 泰弘; 杉田 純一; 腰塚 靖之
    日本輸血細胞治療学会誌, 64, 5, 641, 648, 一般社団法人 日本輸血・細胞治療学会, 2018年, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), <p><背景>肝移植患者は,凝固障害によりしばしば大量出血をきたし,大量の輸血製剤が必要となる.肝移植時のフィブリノゲン製剤の使用で輸血使用量が減少したとの報告があり<sup>1)</sup>,当院でも2012年より脳死肝移植でのフィブリノゲン製剤の使用を導入した.今回,脳死肝移植でのフィブリノゲン製剤の使用による術中出血量と輸血使用量について検討した.<対象>2001年2月から2016年8月の間に当院で脳死肝移植を施行した成人44例を対象とし,フィブリノゲン製剤非投与群25例,投与群19例で術中出血量,輸血使用量の比較検討を行った.また,術中出血量が循環血液量を超えた症例33例(非投与群16例,投与群17例)で同様に検討を行った.<結果>全症例での比較では両群で術中出血量,輸血使用量に有意差は認めなかった.循環血液量以上の出血を来した33例でサブ解析を施行したところ,投与群で術中出血量が有意に減少した.輸血使用量は投与群において濃厚血小板の使用量が有意に減少し,赤血球液,新鮮凍結血漿は減少傾向が認められた.<結論>脳死肝移植ではフィブリノゲン製剤の使用により大量出血を抑制し,輸血使用量を削減できると考えられた.</p>
  • 末梢血幹細胞採取におけるSpectra OptiaⓇ MNCモードとCMNCモードの後方視的検討
    伊藤 誠; 高橋 秀一郎; 宮下 直洋; 後藤 秀樹; 小野澤 真弘; 白鳥 聡一; 杉田 純一; 橋本 大吾; 秋沢 宏次; 佐藤 典宏; 豊嶋 崇徳; 早瀬 英子; 渡邊 千秋; 上床 貴代; 魚住 諒; 林 泰弘; 早坂 光司; 茂木 祐子; 加畑 馨
    日本輸血細胞治療学会誌, 64, 6, 742, 751, 一般社団法人 日本輸血・細胞治療学会, 2018年, [査読有り], [最終著者], [国内誌]
    日本語, 研究論文(学術雑誌), <p><b>背景:</b>Spectra Optia<sup>Ⓡ</sup>は,自動インターフェイス管理システムにより,簡便な操作での末梢血幹細胞採取を可能にした.今回我々は末梢血幹細胞採取において,Spectra Optia<sup>Ⓡ</sup>のMNCモード(MNC群)とCMNCモード(CMNC群)の採取産物のCD34陽性細胞数およびCD34陽性細胞採取効率(採取効率)を後方視的に比較検討した.</p><p><b>対象:</b>2013年8月から2018年2月までに当院で末梢血幹細胞採取を行った233例(自家103例,同種130例)を対象とした.</p><p><b>結果:</b>自家末梢血幹細胞採取における採取産物のCD34陽性細胞数および採取効率は,両群において有意差を認めなかった.同種末梢血幹細胞採取においてMNC群と比較してCMNC群の採取産物のCD34陽性細胞数は有意に高値であり,採取効率も有意に良好であった.同種末梢血幹細胞採取の採取効率に影響する因子として,末梢血血小板数と末梢血ヘモグロビン値が挙げられた.</p><p><b>結語:</b>自家末梢血幹細胞採取においては両群ともに良好な成績であったが,同種末梢血幹細胞採取においては,CMNCモードを用いることでより効率的な採取を行える可能性が示唆された.</p>
  • Improved prognosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults
    Yasuyuki Arai; Tadakazu Kondo; Akio Shigematsu; Junji Tanaka; Kazuteru Ohashi; Takahiro Fukuda; Michihiro Hidaka; Naoki Kobayashi; Koji Iwato; Toru Sakura; Makoto Onizuka; Yukiyasu Ozawa; Tetsuya Eto; Mineo Kurokawa; Kaoru Kahata; Naoyuki Uchida; Yoshiko Atsuta; Shuichi Mizuta; Shinichi Kako
    AMERICAN JOURNAL OF HEMATOLOGY, 93, 1, 47, 57, 2018年01月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • TGF-β Family Signaling in Epithelial Differentiation and Epithelial-Mesenchymal Transition.
    Kahata K; Dadras MS; Moustakas A
    Cold Spring Harbor perspectives in biology, 10, 1, 2018年01月, [招待有り], [筆頭著者], [国際共著], [国際誌]
    英語, 研究論文(学術雑誌), Epithelia exist in the animal body since the onset of embryonic development; they generate tissue barriers and specify organs and glands. Through epithelial-mesenchymal transitions (EMTs), epithelia generate mesenchymal cells that form new tissues and promote healing or disease manifestation when epithelial homeostasis is challenged physiologically or pathologically. Transforming growth factor-βs (TGF-βs), activins, bone morphogenetic proteins (BMPs), and growth and differentiation factors (GDFs) have been implicated in the regulation of epithelial differentiation. These TGF-β family ligands are expressed and secreted at sites where the epithelium interacts with the mesenchyme and provide paracrine queues from the mesenchyme to the neighboring epithelium, helping the specification of differentiated epithelial cell types within an organ. TGF-β ligands signal via Smads and cooperating kinase pathways and control the expression or activities of key transcription factors that promote either epithelial differentiation or mesenchymal transitions. In this review, we discuss evidence that illustrates how TGF-β family ligands contribute to epithelial differentiation and induce mesenchymal transitions, by focusing on the embryonic ectoderm and tissues that form the external mammalian body lining.
  • Development of a Formula to Correct Particle-Enhanced Turbidimetric Inhibition Immunoassay Values so That it More Precisely Reflects High-Performance Liquid Chromatography Values for Mycophenolic Acid.
    Nakano K; Iwami D; Yamada T; Morita K; Yasuda K; Shibuya H; Kahata K; Shinohara N; Shimizu C
    Transplantation direct, 4, 1, e337, 2018年01月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Background: Mycophenolic acid (MPA) concentration measured by homogeneous particle-enhanced turbidimetric inhibition immunoassay (PETINA) may be overestimated due to its cross-reactivity with pharmacologically inactive MPA glucuronide (MPAG), as well as other minor metabolites, accumulated with renal function impairment or co-administered cyclosporine A. In contrast, high-performance liquid chromatography (HPLC) is precise because it can exclude the cross-reactivity. In this study, we assumed HPLC values for MPA (HPLC-MPA) as a reference and aimed to develop a formula correcting PETINA values for MPA (PETINA-MPA) to more precisely reflect HPLC-MPA. Methods: MPA trough concentrations were measured both by HPLC-UV and PETINA in 39 samples issued from 39 solid-organ transplant recipients. MPAG concentrations were also measured using HPLC UV assay. We determined the impacts of renal function and coadministered calcineurin inhibitor on concentrations of MPA and MPAG measured by HPLC. Then, we evaluated the difference between PETINA-MPA and HPLC-MPA. Finally, we develop a formula to reflect HPLC-MPA by using multilinear regression analysis. Results: MPAG concentration was negatively correlated with estimated glomerular filtration rate (eGFR) (R2 = 0.376, P < 0.001), although MPA was not correlated with eGFR. There were no significant differences in MPA or MPAG concentrations per dose between the patients who were co-administered tacrolimus versus cyclosporine A. Finally, we developed the formulas to reflect HPLC-MPA:Formula 1: Estimated MPA concentration = 0.048 + 0.798 × PETINA-MPAFormula 2: Estimated MPA concentration = - 0.059 + 0.800 × PETINA-MPA + 0.002 × eGFRHowever, there was no significant improvement in the coefficient of determination with addition of eGFR in the formula, suggesting that HPLC-MPA can be well predicted by only 1 variable, PETINA-MPA. Conclusions: This study developed a formula so that PETINA-MPA can be corrected to more precisely reflect HPLC-MPA.
  • Novel Ultrasonographic Scoring System of Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation
    Mutsumi Nishida; Kaoru Kahata; Eiko Hayase; Akio Shigematsu; Megumi Sato; Yusuke Kudo; Satomi Omotehara; Takahito Iwai; Junichi Sugita; Hitoshi Shibuya; Chikara Shimizu; Takanori Teshima
    Biology of Blood and Marrow Transplantation, 24, 9, 1896, 1900, Elsevier Inc., 2018年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older
    Koji Kawamura; Shinichi Kako; Shuichi Mizuta; Ken Ishiyama; Jun Aoki; Shingo Yano; Takahiro Fukuda; Naoyuki Uchida; Yukiyasu Ozawa; Tetsuya Eto; Koji Iwato; Heiwa Kanamori; Kaoru Kahata; Tadakazu Kondo; Masashi Sawa; Tatsuo Ichinohe; Yoshiko Atsuta; Yoshinobu Kanda
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23, 12, 2079, 2087, 2017年12月, [査読有り], [国際共著], [国際誌]
    英語, 研究論文(学術雑誌)
  • T-cell depletion effects of low-dose antithymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation.
    Shiratori S; Kosugi-Kanaya M; Hayase E; Okada K; Goto H; Sugita J; Onozawa M; Nakagawa M; Kahata K; Hashimoto D; Endo T; Kondo T; Teshima T
    Transplant immunology, 46, 21, 22, 2017年11月, [査読有り], [国際誌]
    英語
  • Altered oscillation of Doppler-derived renal and renal interlobar venous flow velocities in hypertensive and diabetic patients
    Yusuke Kudo; Taisei Mikami; Mutsumi Nishida; Kazunori Okada; Sanae Kaga; Nobuo Masauzi; Satomi Omotehara; Hitoshi Shibuya; Kaoru Kahata; Chikara Shimizu
    JOURNAL OF MEDICAL ULTRASONICS, 44, 4, 305, 314, 2017年10月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Altered oscillation of Doppler-derived renal and renal interlobar venous flow velocities in hypertensive and diabetic patients
    Yusuke Kudo; Taisei Mikami; Mutsumi Nishida; Kazunori Okada; Sanae Kaga; Nobuo Masauzi; Satomi Omotehara; Hitoshi Shibuya; Kaoru Kahata; Chikara Shimizu
    Journal of Medical Ultrasonics, 45, 1, 197, 197, Springer Tokyo, 2017年10月01日, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Disseminated toxoplasmosis after hematopoietic stem cell transplantation showing unusual magnetic resonance images
    Takahiro Tateno; Masahiro Onozawa; Junichi Hashiguchi; Takashi Ishio; Sayaka Yuzawa; Satomi Matsuoka; Mizuha Kosugi-Kanaya; Kohei Okada; Souichi Shiratori; Hideki Goto; Taichi Kimura; Junichi Sugita; Masao Nakagawa; Daigo Hashimoto; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Takeshi Kondo; Shinya Tanaka; Satoshi Hashino; Takanori Teshima
    TRANSPLANT INFECTIOUS DISEASE, 19, 4, 2017年08月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Computer-Aided Diagnosis of Focal Liver Lesions Using Contrast-Enhanced Ultrasonography With Perflubutane Microbubbles
    Satoshi Kondo; Kazuya Takagi; Mutsumi Nishida; Takahito Iwai; Yusuke Kudo; Kouji Ogawa; Toshiya Kamiyama; Hitoshi Shibuya; Kaoru Kahata; Chikara Shimizu
    IEEE TRANSACTIONS ON MEDICAL IMAGING, 36, 7, 1427, 1437, 2017年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Risk factors of human herpesvirus 6 encephalitis/myelitis after allogeneic hematopoietic stem cell transplantation
    Naohiro Miyashita; Tomoyuki Endo; Masahiro Onozawa; Daigo Hashimoto; Takeshi Kondo; Katsuya Fujimoto; Kaoru Kahata; Junichi Sugita; Hideki Goto; Toshihiro Matsukawa; Satoshi Hashino; Takanori Teshima
    TRANSPLANT INFECTIOUS DISEASE, 19, 3, 2017年06月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • MALDI-TOF MS in post-transplant bloodstream infections: reliable identification of causative bacteria in the neutropenic phase
    M. Kanaya; Y. Hayashi; D. Hashimoto; T. Endo; J. Sugita; H. Ohigashi; J. Hashiguchi; T. Matsukawa; S. Matsuoka; M. Kosugi-Kanaya; H. Goto; M. Onozawa; K. Kahata; K. Fujimoto; T. Kondo; K. Akizawa; H. Shibuya; C. Shimizu; T. Teshima
    BONE MARROW TRANSPLANTATION, 52, 5, 778, 780, 2017年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • 生体腎移植後にIgM抗体によるPassenger Lymphocyte Syndromeが疑われた1症例
    魚住 諒; 加畑 馨; 渡邊 千秋; 伊藤 誠; 上床 貴代; 林 泰弘; 岩見 大基; 渋谷 斉; 清水 力
    日本輸血細胞治療学会誌, 63, 2, 148, 148, (一社)日本輸血・細胞治療学会, 2017年04月
    日本語
  • TGF-β Family Signaling in Ductal Differentiation and Branching Morphogenesis.
    Kahata K; Maturi V; Moustakas A
    Cold Spring Harbor perspectives in biology, 10, 3, 2017年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Epithelial cells contribute to the development of various vital organs by generating tubular and/or glandular architectures. The fully developed forms of ductal organs depend on processes of branching morphogenesis, whereby frequency, total number, and complexity of the branching tissue define the final architecture in the organ. Some ductal tissues, like the mammary gland during pregnancy and lactation, disintegrate and regenerate through periodic cycles. Differentiation of branched epithelia is driven by antagonistic actions of parallel growth factor systems that mediate epithelial-mesenchymal communication. Transforming growth factor-β (TGF-β) family members and their extracellular antagonists are prominently involved in both normal and disease-associated (e.g., malignant or fibrotic) ductal tissue patterning. Here, we discuss collective knowledge that permeates the roles of TGF-β family members in the control of the ductal tissues in the vertebrate body.
  • 中央診療部門における成人先天性心疾患および小児の心エコーの実施に向けた取り組み
    横山 しのぶ; 山田 聡; 佐々木 理; 岩野 弘幸; 西野 久雄; 井上 真美子; 武田 充人; 西田 睦; 澁谷 斉; 加畑 馨; 清水 力
    日本成人先天性心疾患学会雑誌, 6, 1, 147, 147, 日本成人先天性心疾患学会, 2017年01月
    日本語
  • ミコフェノール酸血中濃度測定における代謝産物が与える影響
    中野 恵一; 山田 武宏; 安田 慶子; 山下 直樹; 澁谷 斉; 加畑 馨; 井関 健; 清水 力
    日本臨床検査自動化学会会誌, 41, 5, 659, 664, (一社)日本臨床検査自動化学会, 2016年11月
    日本語, 免疫抑制薬として用いられているミコフェノール酸モフェチルは、消化管で吸収され、加水分解を受けてミコフェノール酸(MPA)に変換される。さらに、MPAは肝臓でグルクロン酸抱合体(MPAG)に代謝され、その大部分が腎臓から排泄される。また、一部は胆汁へ排泄され、腸管循環によりMPAとして再吸収され、血中へ移行する。MPA濃度の測定方法は、従来からHPLC法を原理として測定されてきた。近年では、簡便かつ迅速に測定できる免疫学的測定法(EMIT法やPETINA法)が開発され普及してきているが、免疫学的測定法は代謝産物と交差反応することが報告されている。今回、自験44例のMPAG濃度を測定し、腎機能や併用カルシニューリン阻害剤がMPAGの蓄積にどの程度影響しているか検討するとともに、MPAG蓄積がMPAの血中濃度測定へ及ぼす影響について検討した。結果、MPAG蓄積に対して腎機能とシクロスポリンが有意な影響を及ぼしていることが明らかになり、PETINA法でMPAを測定する際にはこれらの影響を考慮する必要があると考えられた。
  • 生体肝移植後におけるリンパ球クロスマッチによるDSAモニタリングの有用性
    伊藤 誠; 加畑 馨; 上床 貴代; 魚住 諒; 林 泰弘; 渡邊 千秋; 澁谷 斉; 後藤 了一; 嶋村 剛; 清水 力
    MHC: Major Histocompatibility Complex, 23, 2Suppl., 86, 86, (一社)日本組織適合性学会, 2016年10月
    日本語
  • A Comparison of Outcomes for Cord Blood Transplantation and Unrelated Bone Marrow Transplantation in Adult Aplastic Anemia
    Yachiyo Kuwatsuka; Junya Kanda; Hirohito Yamazaki; Takehiko Mori; Koichi Miyamura; Shinichi Kako; Naoyuki Uchida; Kazuteru Ohashi; Yukiyasu Ozawa; Yoshiyuki Takahashi; Chiaki Kato; Koji Iwato; Ken Ishiyama; Hikaru Kobayashi; Tetsuya Eto; Kaoru Kahata; Jun Kato; Toshihiro Miyamoto; Koji Kato; Shinicihro Mori; Yoshiko Atsuta; Fumihiko Kimura; Yoshinobu Kanda
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22, 10, 1836, 1843, 2016年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Long-term echocardiographic evaluation of valvular lesions in a patient with nonbacterial thrombotic endocarditis associated with advanced uterine cancer.
    Shinobu Yokoyama; Hiroyuki Iwano; Satoshi Yamada; Mahito Takeda; Sanae Kaga; Masahiro Nakabachi; Hisao Nishino; Ayako Ichikawa; Ayumu Abe; Kazunori Okada; Daisuke Murai; Taichi Hayashi; Mutsumi Nishida; Hitoshi Shibuya; Kaoru Kahata; Chikara Shimizu; Taisei Mikami; Hiroyuki Tsutsui
    Journal of cardiology cases, 14, 3, 82, 86, 2016年09月, [国内誌]
    英語, 研究論文(学術雑誌), Nonbacterial thrombotic endocarditis (NBTE) is characterized by the deposition of thrombi on previously undamaged heart valves in the absence of bacteremia and predominantly affects patients with hypercoagulable state. Although the diagnosis is usually based on transthoracic echocardiography, little is known about the serial changes of the vegetation in response to treatment. We experienced a 42-year-old woman with advanced uterine cancer and asymptomatic cerebral embolization. Plasma d-dimer level was markedly elevated and echocardiography showed highly mobile masses attached to the anterior and posterior mitral leaflets with moderate regurgitation. Based on these findings, she was diagnosed as having NBTE associated with uterine cancer and intravenous administration of heparin and chemotherapy were performed. Follow-up echocardiography revealed the disappearance of the vegetation and reduction of mitral regurgitation. Uterine cancer was successfully treated by surgery and recurrence of the valvular lesion did not occur. .
  • Transient human anti-mouse antibody generated with immune enhancement in a carbohydrate antigen 19-9 immunoassay after surgical resection of recurrent cancer
    Keiichi Nakano; Keiko Yasuda; Hitoshi Shibuya; Takanori Moriyama; Kaoru Kahata; Chikara Shimizu
    ANNALS OF CLINICAL BIOCHEMISTRY, 53, 4, 511, 515, 2016年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHD
    Toshihiro Matsukawa; Daigo Hashimoto; Junichi Sugita; Seitarou Nakazawa; Takae Matsushita; Haruhiko Kashiwazaki; Hideki Goto; Masahiro Onozawa; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Takeshi Kondo; Satoshi Hashino; Yutaka Yamazaki; Takanori Teshima
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 104, 1, 117, 124, 2016年07月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • The Effectiveness of Noninvasive Transabdominal Ultrasound Evaluation in the Early Diagnosis of Hepatic Veno-Occlusive Disease After Hematopoietic Stem Cell Transplantation
    Mutsumi Nishida; Kaoru Kahata; Akio Shigematsu; Megumi Satoh; Yusuke Kudo; Satomi Omotehara; Tatsunori Horie; Akihiro Iguchi; Junichi Sugita; Hitoshi Shibuya; Chikara Shimizu; Takanori Teshima
    GASTROENTEROLOGY, 150, 4, S922, S922, 2016年04月
    英語
  • 造影超音波検査を施行した悪性リンパ腫肝病変の1症例
    岩井 孝仁; 西田 睦; 佐藤 恵美; 工藤 悠輔; 表原 里実; 藤田 裕美; 真鍋 徳子; 小松 嘉人; 加畑 馨; 清水 力
    超音波医学, 43, 1, 115, 122, 一般社団法人 日本超音波医学会, 2016年
    日本語, 症例は70歳代,女性.主訴は心窩部痛.ALT持続正常HCVキャリアで,前医にて経過観察中であった.1年半前の超音波検査(US)で,肝S4に均質的な低エコー域を認めていたが,明らかな腫瘤としては認識されず,同時期のCTでも異常所見は指摘されなかったため経過観察されていた.経過観察中のUSで低エコー域は明瞭化,サイズ増大し明らかな腫瘤性病変として認識された.CTにては肝腫瘤および胃食道接合部に肥厚を認め,胃食道接合部癌と転移性肝癌の疑いで,精査加療目的に当院紹介となった.当院USにて,肝S4を主座とする境界明瞭な最大径91 mmの充実性腫瘤を認めた.辺縁は低エコーで中心部は高エコーを呈していた.肝門部には境界明瞭で低エコーのリンパ節腫大を多数認めた.Sonazoid®造影超音波検査(CEUS)では,動脈相で辺縁から内部に流入する微細点状の造影効果を認め,主に辺縁は強く造影されたが,中心部の造影効果はみられなかった.門脈相で辺縁の造影効果は減弱し,後血管相で造影欠損像を呈した.CTでは,内部に変性ないし壊死を疑う低吸収域を伴う乏血性腫瘤の形態であった.また,肝門部の他,頸部と左腋窩にリンパ節腫大像を認めた.診断目的で肝腫瘍生検が施行され,病理組織学的診断は,びまん性大細胞型B細胞リンパ腫であり,悪性リンパ腫の肝浸潤と診断された.悪性リンパ腫の肝臓病変は,低エコーで均質な性状を呈する腫瘤性病変が多く,中心部が壊死を呈する症例の報告は少ない.今回,CEUSを施行した中心部に変性または壊死を疑う悪性リンパ腫肝浸潤の1症例を経験したので報告する.
  • The protein kinase LKB1 negatively regulates bone morphogenetic protein receptor signaling
    Erna Raja; Kalliopi Tzavlaki; Robin Vuilleumier; Karolina Edlund; Kaoru Kahata; Agata Zieba; Anita Moren; Yukihide Watanabe; Iryna Voytyuk; Johan Botling; Ola Soderberg; Patrick Micke; George Pyrowolakis; Carl-Henrik Heldin; Aristidis Moustakas
    ONCOTARGET, 7, 2, 1120, 1143, 2016年01月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • BDバクテックシステムを用いた新しい無菌試験法の検討
    魚住 諒; 岩崎 澄央; 福元 達也; 秋沢 宏次; 渋谷 斉; 加畑 馨; 清水 力
    臨床病理, 63, 補冊, 141, 141, (一社)日本臨床検査医学会, 2015年10月
    日本語
  • The high mobility group A2 protein epigenetically silences the Cdh1 gene during epithelial-to-mesenchymal transition
    E-Jean Tan; Kaoru Kahata; Oskar Idas; Sylvie Thuault; Carl-Henrik Heldin; Aristidis Moustakas
    NUCLEIC ACIDS RESEARCH, 43, 1, 162, 178, 2015年01月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Deregulation of hyaluronan synthesis, degradation and binding promotes breast cancer
    Paraskevi Heldin; Kaustuv Basu; Berit Olofsson; Helena Porsch; Inna Kozlova; Kaoru Kahata
    JOURNAL OF BIOCHEMISTRY, 154, 5, 395, 408, 2013年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Fungemia due to Trichosporon dermatis in a patient with refractory Burkitt's leukemia
    Satoshi Hashino; Shojiro Takahashi; Rena Morita; Hiroe Kanamori; Masahiro Onozawa; Takahito Kawamura; Kaoru Kahata; Takeshi Kondo; Issei Tokimatsu; Takashi Sugita; Koji Akizawa; Masahiro Asaka
    Blood Research, 48, 2, 154, 156, 2013年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Context-dependent action of transforming growth factor β family members on normal and cancer stem cells.
    Caja L; Kahata K; Moustakas A
    Current pharmaceutical design, 18, 27, 4072, 4086, 2012年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Clinical impact of cycling the administration of antibiotics for febrile neutropenia in Japanese patients with hematological malignancy
    S. Hashino; L. Morita; H. Kanamori; M. Takahata; M. Onozawa; M. Nakagawa; T. Kawamura; F. Fujisawa; K. Kahata; K. Izumiyama; M. Yonezumi; K. Chiba; T. Kondo; M. Asaka
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 31, 2, 173, 178, 2012年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Complete Remission Following Chemotherapy with Low-dose Cytosine Arabinoside and Macrophage Colony-stimulating Factor/Granulocyte Colony-stimulating Factor in a Patient with Relapsed Acute Myeloid Leukemia after Stem Cell Transplantation
    Kohei Okada; Asumi Higashiyama; Mutsumi Takahata; Masahiro Onozawa; Kaoru Kahata; Sachiko Ando; Junji Tanaka; Satoshi Hashino; Masahiro Imamura
    INTERNAL MEDICINE, 51, 20, 2937, 2941, 2012年, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Cdc6 expression represses E-cadherin transcription and activates adjacent replication origins
    Maria Sideridou; Roubini Zakopoulou; Konstantinos Evangelou; Michalis Liontos; Athanassios Kotsinas; Emmanouil Rampakakis; Sarantis Gagos; Kaoru Kahata; Kristina Grabusic; Kalliopi Gkouskou; Ioannis P. Trougakos; Evangelos Kolettas; Alexandros G. Georgakilas; Sinisa Volarevic; Aristides G. Eliopoulos; Maria Zannis-Hadjopoulos; Aristidis Moustakas; Vassilis G. Gorgoulis
    JOURNAL OF CELL BIOLOGY, 195, 7, 1123, 1140, 2011年12月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • [Successful treatment with reduced-intensity cord blood transplantation for acute myeloid leukemia with complete tetraploidy (92, XXXX)].
    Iwasaki J; Onozawa M; Takahashi S; Okada K; Takahata M; Shigematsu A; Kahata K; Kondo T; Hashino S; Imamura M; Asaka M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 52, 3, 124, 128, 「臨床血液」編集部, 2011年03月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), A 56-year-old female was diagnosed with acute myeloid leukemia (FAB: AML-M1). G-banding karyotype of her bone marrow showed complete tetraploidy (92, XXXX [24/24]). Although she achieved complete remission (CR) after induction therapy and maintained CR during consolidation therapy, relapse occurred only 2 months after discharge. When the relapse occurred, bone marrow karyotypic analysis showed complete tetraploidy again. The patient received reduced-intensity cord blood transplantation (RI-CBT), which induced CR for the second time. The patient is currently alive 24 months after transplantation and there have not been any signs of recurrence to date. There have been a few reports of AML with near-tetraploidy, but cases of AML with complete tetraploidy are extremely rare. Tetraploid AML has been reported to have a poor prognosis and there have been very few cases maintaining CR over the long term after chemotherapy alone. This is the first case of complete tetraploid AML successfully treated by RI-CBT. The clinical course of this case suggests that hematopoietic stem cell transplantation during the first CR phase should be considered a treatment option for tetraploid AML.
  • Increased risk of bacterial infection after engraftment in patients treated with allogeneic bone marrow transplantation following reduced-intensity conditioning regimen.
    Shigematsu A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Yamaguchi K; Wakasa K; Takahata M; Goto H; Ito S; Takemura R; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Transplant infectious disease : an official journal of the Transplantation Society, 12, 5, 412, 420, 2010年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Although bacterial infection is a major cause of death even after reduced-intensity conditioning (RIC) for allogeneic stem cell transplantation (SCT), little is known about the epidemiology and risk factors. The incidence of bacterial infection in 43 patients who received allogeneic bone marrow transplantation (BMT) using a RIC regimen was compared with that in 68 patients who received BMT using a myeloablative conditioning regimen, and risk factors for bacterial infection were identified. Before engraftment, incidences of febrile neutropenia (FN) and documented infections (DI) were significantly decreased in RIC patients (FN: 59.5% vs. 89.6%, P<0.01, DI: 4.8% vs. 17.9%, P<0.01). However, incidence of bacterial infection was significantly increased in RIC patients in the post-engraftment phase (53.8% vs. 11.1%, log-rank, P<0.01). Blood stream was the most frequent focus of infection in both groups. In multivariate analysis, RIC and acute graft-versus-host disease were revealed to be significant risk factors for bacterial infection in this phase. In summary, risk of bacterial infection after engraftment was significantly higher in RIC patients, although infection was decreased before engraftment, and we need to develop a RIC-specific strategy against bacterial infection after RIC SCT.
  • [Intravascular large B-cell lymphoma with massive pulmonary lesions].
    Higashiyama A; Hashino S; Onozawa M; Takahata M; Okada K; Kahata K; Taniguchi N; Nasuhara Y; Kubota K; Fujimoto N; Matsuno Y; Nishimura M; Asaka M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 51, 5, 353, 356, 「臨床血液」編集部, 2010年05月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), A 61-year-old man was admitted to our hospital with dyspnea on effort. Neither computed tomography scan nor chest X-ray film detected any specific findings that could explain hypoxemia. Since (67)Ga scintigraphy showed abnormal uptake in the bilateral lungs, transbronchial lung biopsy (TBLB) was performed. The TBLB specimen was diagnosed as intravascular large B-cell lymphoma (IVLBCL). There was no involvement of any other organ considered typical of IVLBCL. In cases showing clinical findings such as hypoxia despite mild pulmonary radiographic changes, a definitive diagnosis should be made using methods such as TBLB with consideration given to the possibility of IVLBCL.
  • Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): Clinical efficacy in high-risk patients
    Mutsumi Takahata; Satoshi Hashino; Kohei Okada; Masahiro Onozawa; Kaoru Kahata; Junichi Sugita; Akio Shigematsu; Takeshi Kondo; Satoshi Yamamoto; Tomoyuki Endo; Mitsufumi Nishio; Yoichi M. Ito; Junji Tanaka; Takao Koike; Masahiro Asaka; Masahiro Imamura
    AMERICAN JOURNAL OF HEMATOLOGY, 85, 4, 243, 248, 2010年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation
    Takeshi Kondo; Atsushi Yasumoto; Kotaro Arita; Jun-ichi Sugita; Akio Shigematsu; Kohei Okada; Mutsumi Takahata; Masahiro Onozawa; Kaoru Kahata; Yukari Takeda; Masato Obara; Satoshi Yamamoto; Tomoyuki Endo; Mitsufumi Nishio; Norihiro Sato; Junji Tanaka; Satoshi Hashino; Takao Koike; Masahiro Asaka; Masahiro Imamura
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 91, 2, 310, 321, 2010年03月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • [Pyogenic spondylitis following unrelated hematopoietic stem cell transplantation].
    Mukaiyama Y; Hashino S; Onozawa M; Okada K; Takahata M; Kahata K; Asaka M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 50, 12, 1706, 1710, 「臨床血液」編集部, 2009年12月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), Pyogenic spondylitis is regarded as a rare infectious disease. The incidence of this disease has been increasing recently due to an increase in the ratio of elderly people in the population as well as an increase in immunocompromised hosts complicated by cancer, diabetes mellitus and liver cirrhosis. Allogeneic hematopoietic stem cell transplantation (HSCT) is now performed widely as a curative treatment for various malignant hematological diseases. However, allogeneic HSCT causes chronic immunocompromise. There is no case report describing infectious spondylitis after HSCT. Here we describe a case of infectious spondylitis after HSCT and discuss risk factors and treatment. The patient was a 56-year-old female with AML-M1 who underwent allogeneic HSCT in our hospital. She developed back pain and fever about 150 days after HSCT and became unable to walk due to the severity of back pain. MRI T1 images showed a low intensity area, T2 images showed a high intensity area and Gd-DTPA-enhanced images showed a high intensity area at the S1-2 disk space. Clinical findings and MRI findings suggested pyogenic spondylitis. Back pain improved gradually after conservative treatment with meropenem (MEPM) for two weeks. After 4 weeks of MEPM administration, she had fully recovered and there has not been any recurrence of back pain to date. In conclusion, pyogenic spondylitis should be considered in the differential diagnoses for HSCT recipients with severe back pain.
  • Iron deficiency anemia successfully treated by Helicobacter pylori eradication in a patient with idiopathic thrombocytopenic purpura.
    MORITA R; HASHINO S; OKADA K; TAKAHATA M; ONOZAWA M; KAHATA K; KONDO T; IMAMURA M; ASAKA M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 50, 11, 1655, 1657, 2009年11月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), A 53-year-old woman had demonstrated idiopathic thrombocytopenic purpura (ITP) and iron deficiency anemia (IDA) since 1978. Although she was treated with prednisolone for ITP and oral iron compounds for IDA, neither ITP nor IDA showed any improvement. Since her (13)C-urea breath test was positive, Helicobacter pylori (H. pylori) eradication therapy was performed in 2001. The therapy was effective for IDA but not for ITP. Analysis of cases such as this will be useful for clarifying the mechanisms underlying the development of ITP and IDA associated with H. pylori.
  • LOW-DOSE THALIDOMIDE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    K. O. Kohei; S. Ando; S. Hasino; H. Huse; R. Morita; M. Takahata; M. Onozawa; K. Kahata; T. Kondo; S. Ota; T. Kawamura; M. Kurosawa; K. Aikawa; T. Ogawa; S. Suzuki; S. Takahashi; K. Izumiyama; H. Iwasaki; M. Maemori; H. Sakai; M. Asaka
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 94, 619, 620, 2009年06月
    英語
  • Regimen-Related Mucosal Injury of the Gut Increased the Incidence of CMV Disease after Allogeneic Bone Marrow Transplantation
    Akio Shigematsu; Atsushi Yasumoto; Satoshi Yamamoto; Junichi Sugita; Takeshi Kondo; Masahiro Onozawa; Kaoru Kahata; Tomoyuki Endo; Shuichi Ota; Norihiro Sato; Mutsumi Takahata; Kohei Okada; Junji Tanaka; Satoshi Hashino; Mitsufumi Nishio; Takao Koike; Masahiro Asaka; Masahiro Imamura
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15, 6, 679, 685, 2009年06月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Endoscopic biliary drainage for choledocholithiasis in a patient with aplastic anemia before hematological engraftment after allogeneic transplantation.
    Okada K; Hashino S; Takahata M; Onozawa M; Kahata K; Kondo T; Imamura M; Asaka M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 50, 5, 419, 423, 一般社団法人 日本血液学会, 2009年05月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), 症例は30歳代,男性で,1997年発症の重症再生不良性貧血である。前医でmPSLパルス療法,ATG, cyclosporineで治療が行われたが,寛解・再燃を繰り返し,徐々に治療耐性となったため,同種骨髄移植目的に当院へ転院となった。移植前精査で,無症候性胆嚢胆石・総胆管結石を認めたが,白血球が低値であることから移植後に結石除去を行う方針とした。転院後,発熱を認め,G-CSFを連日投与しても好中球100/μl以下であり発熱性好中球減少症の状態であった。抗生剤投与により解熱後,骨髄非破壊的前処置でHLA一致ドナーより,非血縁者間同種骨髄移植を行った。移植後day 9に総胆管結石に伴う閉塞性胆管炎を発症した。無菌解除の上,内視鏡的にEBDチューブを挿入し,その後胆管炎症状は軽快した。day 24に骨髄生着し,血小板回復後のday 57にESTを施行し,総胆管結石の排石を行った。
    本症例は生着前の時期に閉塞性胆管炎を発症したが,内科的治療(EBD, 抗生剤投与)により救命しえた。移植前の無症候性胆道結石の扱いについて,定まった方針はなく,その適応に関しては,今後の症例の蓄積とさらなる検討が必要と考えられた。しかし一方で本症例により,たとえ移植前に手術や処置ができなくても,内科的治療により感染を乗り切ることができる可能性も示唆された。
  • Donor cell-derived sarcoidosis after allogeneic BMT
    R. Morita; S. Hashino; K. Kubota; M. Onozawa; K. Kahata; T. Kondo; S. Suzuki; Y. Matsuno; M. Imamura; M. Asaka
    BONE MARROW TRANSPLANTATION, 43, 6, 507, 508, 2009年03月
    英語
  • Pseudomembranous tracheobronchial aspergillosis.
    Onozawa M; Takahashi S; Kanamori H; Kahata K; Kondo T; Hashino S; Asaka M
    Internal medicine journal, 39, 1, 65, 66, 2009年01月, [査読有り]
  • 薬剤性過敏症症候群類似の経過を辿った低ガンマグロブリン血症
    白井 慎一; 橋野 聡; 守田 玲菜; 小野澤 真弘; 川村 孝仁; 加畑 馨; 近藤 健; 今村 雅寛; 浅香 正博
    臨床血液, 50, 1, 23, 28, (一社)日本血液学会-東京事務局, 2009年01月
    日本語, 30歳男性。患者は上腹部痛および黒色便が出現し近医を受診、十二指腸潰瘍を認め入院後、肝機能障害と発熱、上半身に紅斑が出現し、肝生検で巨細胞性肝炎の所見からウイルス性肝炎を疑い、天然型インターフェロンα投与が行なわれた。その結果、皮疹は軽快したものの、リンパ球の減少をはじめガンマグロブリン低値、異型リンパ球出現、敗血症を認めたため、著者らの施設へ紹介入院となった。所見では発熱と多数の表在リンパ節腫脹がみられたが、3日目以降、解熱となり、リンパ節腫脹も縮小傾向となった。一方、FDG-PETを行なったところ、両側鼠径、脇窩リンパ節に集積が認められ、入院時の可溶性IL-2レセプター高値から悪性リンパ腫と考えたが、左鼠径リンパ節生検でDermatopathic lymphoadenopathyと診断された。病態が薬剤性過敏症症候群と類似していたためヒトヘルペスウイルス(HHV)-6型の抗体価測定を行なったところ、前医で160倍であったHHV-6 IgGは2560倍に上昇していた。以後、患者は症状が軽減し、退院となった。
  • [Hypogammaglobulinemia with a clinical course similar to that of drug-induced hypersensitivity syndrome].
    Shirai S; Hashino S; Morita R; Onozawa M; Kawamura T; Kahata K; Kondo T; Imamura M; Asaka M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 50, 1, 23, 28, 2009年01月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), A 30-year-old man consulted a local hospital because of upper abdominal pain and tarry stool and was admitted because of duodenal ulcer and hepatic dysfunction. On the fifth hospital day, he developed fever and erythema on the upper body. Liver biopsy demonstrated giant cell hepatitis, and interferon alpha was therefore administered. Liver function improved, though total bilirubin increased to 22.3 mg/dl. The eruption and fever improved in the 3rd hospital week, deteriorated again in the 5th hospital week, and then improved again in the 8th hospital week. Thereafter, he was transferred to our hospital for detailed examination of atypical lymphocytosis, lymphopenia, and hypogammaglobulinemia. Many lymph nodes measuring about 1 cm were detected by palpation. After admission to our hospital, lymphoadenopathy and fever improved. We measured the level of HHV-6 antibody since the clinical course was similar to that of drug-induced hypersensitivity syndrome (DIHS). HHV-6 IgG was x2,560, although it had been x160 at the previous hospital. The clinical course appeared similar to that of DIHS, but drugs known to cause DIHS had not been administered.
  • HB Vaccination in the Prevention of Viral Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Previous HBV Infection
    Masahiro Onozawa; Satoshi Hashino; Stephanie Darmanin; Kohei Okada; Rena Morita; Mutsumi Takahata; Akio Shigematsu; Kaoru Kahata; Takeshi Kondo; Junji Tanaka; Masahiro Imamura; Masahiro Asaka
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 14, 11, 1226, 1230, 2008年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma
    Rena Morita; Satoshi Hashino; Shinichi Shirai; Noriaki Fujita; Masahiro Onozawa; Kaoru Kahata; Takeshi Kondo; Masahiro Imamura; Masahiro Asaka
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 88, 2, 248, 250, 2008年09月, [査読有り], [国内誌]
    英語
  • Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
    Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
    International journal of laboratory hematology, 30, 4, 292, 299, 2008年08月, [査読有り]
  • A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): Clinical impact of graft-versus-leukemia/lymphoma effect
    Souichi Shiratori; Atsushi Yasumoto; Junji Tanaka; Akio Shigematsu; Satoshi Yamamoto; Mitsufumi Nishio; Satoshi Hashino; Rena Morita; Mutsumi Takahata; Masahiro Onozawa; Kaoru Kahata; Takeshi Kondo; Shuichi Ota; Kentaro Wakasa; Junichi Sugita; Takao Koike; Masahiro Asaka; Masaharu Kasai; Masahiro Imamura
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 14, 7, 817, 823, 2008年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • HBV REVERSE SEROCONVERSION AND INTERVENTION WITH VACCINATION AFTER ALLOGENEIC HSCT IN PATIENTS WITH PREVIOUS HBV INFECTION
    M. Onozawa; S. Hashino; R. Morita; K. Kahata; T. Kondo; J. Tanaka; M. Imamura; M. Asaka
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 93, 182, 182, 2008年06月
    英語
  • Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia
    Akio Shigematsu; Takeshi Kondo; Satoshi Yamamoto; Junichi Sugita; Masahiro Onozawa; Kaoru Kahata; Tomoyuki Endo; Soichi Shiratori; Shuichi Ota; Masato Ohara; Kentaro Wakasa; Mutsumi Takahata; Yukari Takeda; Junji Tanaka; Satoshi Hashino; Mitsufumi Nishio; Takao Koike; Masahiro Asaka; Masahiro Imamura
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 14, 5, 568, 575, 2008年05月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Graft-versus-tumor effect after reduced-intensity allogeneic hematopoietic stem cell transplantation in a patient with advanced colon cancer
    Satoshi Hashino; Sumiko Kobayashi; Mutsumi Takahata; Masahiro Onozawa; Masao Nakagawa; Takahito Kawamura; Fumie Fujisawa; Koh Izumiyama; Kaoru Kahata; Takeshi Kondo; Masahiro Asaka
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 13, 2, 176, 180, 2008年04月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Favourable outcomes of allogeneic haematopoietic stem cell transplantation with reduced-intensity conditioning after failure of previous transplantation
    K. Kahata; S. Hashino; L. Morita; M. Onozawa; T. Kondo; M. Imamura; M. Asaka
    BONE MARROW TRANSPLANTATION, 41, S209, S209, 2008年03月
    英語
  • Chimerism and T-cell receptor repertoire analysis after unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous stem cell transplantation for multiple myeloma
    T. Toubai; D. Hirate; Y. Shono; S. Ota; M. Ibata; S. Mashiko; J. Sugita; A. Shigematsu; Y. Miura; N. Kato; S. Umehara; K. Kahata; Y. Tsutsumi; N. Iwao; N. Toyoshima; J. Tanaka; M. Asaka; M. Imamura
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 30, 1, 75, 81, 2008年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • [Granulocyte transfusion for the treatment of prolonged pneumonia in a patient with MDS-RAEB-2 at allogeneic hematopoietic stem cell transplantation].
    Morita R; Hashino S; Takahashi S; Kanamori H; Onozawa M; Kahata K; Kondo T; Imamura M; Asaka M
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 49, 2, 89, 93, 2008年02月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), We report that granulocyte transfusion (GTX) was effective for prolonged pneumonia at allogeneic bone marrow transplantation. A 58-year-old man with MDS-RAEB-2 was admitted to our hospital for allogeneic bone marrow transplantation. He was complicated with pneumonia, which was not improved with G-CSF and antibiotics. We therefore decided to perform a GTX transplantation. During the period of neutropenia, pneumonia did not deteriorate. A combination of allogeneic stem cell transplantation and GTX is expected not only to improve transplantation results but also to expand the adaptation for transplantation. However, detailed investigation of the effect of GTX in allogeneic stem cell transplantation should be performed, and more cases should be accumulated.
  • Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation
    Satoshi Hashino; Lena Morita; Mutsumi Takahata; Masahiro Onozawa; Masao Nakagawa; Takahito Kawamura; Fumie Fujisawa; Kaoru Kahata; Koh Izumiyama; Masakatsu Yonezumi; Koji Chiba; Takeshi Kondo; Masahiro Asaka
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 87, 1, 91, 97, 2008年01月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Durable remission of Sézary syndrome after unrelated bone marrow transplantation by reduced-intensity conditioning.
    Kahata K; Hashino S; Takahata M; Fujisawa F; Kondo T; Kobayashi S; Fujita Y; Shimizu H; Imamura M; Asaka M
    Acta haematologica, 120, 1, 14, 18, 2008年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • A chimeric gene, FIP1L1-RAR alpha, is isolated from t(4;17)-positive acute promyelocytic leukemia; a report of cloning and functional analysis
    Takeshi Kondo; Akio Mori; Masahiro Onozawa; Kaoru Kahata; Satoshi Hashino; Junji Tanaka; Masahiro Imamura; Masanobu Morioka; Masahiro Asaka
    BLOOD, 110, 11, 539A, 539A, 2007年11月
    英語
  • Acute-onset pancytopenia in a postpartum lactating woman
    Masahiro Onozawa; Satoshi Hashino; Shojiro Takahashi; Rena Morita; Hiroe Kanamori; Kaoru Kahata; Takeshi Kondo; Masahiro Asaka
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 86, 4, 374, 376, 2007年11月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Efficacy of micafungin in prophylaxis against invasive fungal infections in patients undergoing allogeneic hematopoietic stem cell transplantation
    S. Hashino; K. Kahata; M. Onozawa; T. Kondo; H. Kanamori; S. Takahashi; M. Asaka
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 92, 452, 452, 2007年06月
    英語
  • Successful reduced-intensity stem cell transplantation with cord blood for a poor-prognosis adult with refractory chronic active Epstein-Barr virus infection
    Masao Nakagawa; Satoshi Hashino; Mutsumi Takahata; Takahito Kawamura; Fumie Fujisawa; Kaoru Kahata; Takeshi Kondo; Masahiro Imamura; Sachiko Ando; Masahiro Asaka
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 85, 5, 443, 445, 2007年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients
    Masahiro Onozawa; Satoshi Hashino; Mutsumi Takahata; Fumie Fujisawa; Takahito Kawamura; Masao Nakagawa; Kaoru Kahata; Takeshi Kondo; Shuichi Ota; Junji Tanaka; Masahiro Imamura; Masahiro Asaka
    JOURNAL OF CLINICAL MICROBIOLOGY, 44, 12, 4441, 4443, 2006年12月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Chimeric leukemic protein PLZF/RAR alpha functions as an adoptor for Cul3-Based E3 ubiquitin ligase to regulate proteosomal degradation of RXR alpha.
    Masahiro Onozawa; Takeshi Kondo; Hiroe Kanamori; Kaoru Kahata; Satoshi Hashino; Masahiro Asaka
    BLOOD, 108, 11, 545A, 545A, 2006年11月
    英語
  • PNH-MDSに対するReduced intensity stem cell transplantation(RIST)の1例
    東梅 友美; 田中 淳司; 太田 秀一; 比嘉 敏夫; 杉田 純一; 加藤 菜穂子; 三浦 洋子; 近藤 恵一; 加畑 馨; 岩尾 憲明; 浅香 正博; 今村 雅寛
    日本輸血学会雑誌, 52, 1, 65, 65, (一社)日本輸血・細胞治療学会, 2006年03月
    日本語
  • 造血器悪性腫瘍患者の好中球減少時におけるイトラコナゾールカプセル剤200mg/日投与の真菌感染症の予防効果
    東梅 友美; 田中 淳司; 太田 秀一; 加藤 菜穂子; 梅原 伸太郎; 加畑 馨; 豊島 経康; 浅香 正博; 今村 雅寛
    The Japanese Journal of Antibiotics, 58, 6, 507, 517, (公財)日本感染症医薬品協会, 2005年12月
    日本語, イトラコナゾール(ITCZ)200mg/日予防投与の有用性を再確認するため,造血器悪性腫瘍患者37例を対象とする非対照,プロスペクティブ試験を実施した.急性骨髄性白血病,急性リンパ性白血病,悪性リンパ腫,成人T細胞性白血病,多発性骨髄腫等の造血器悪性腫瘍の患者で,がん化学療法等により好中球減少が予想される症例を対象とした.ITCZ投与中の好中球減少は,31例であったが,真菌感染症の発症エピソードは全例において認めなかった.監視培養陽性率はStage III~IV期の悪性リンパ腫において認めた好中球減少持続期間の長さ及び好中球数最低値の低さと相関した.便秘2例及び痺れ2例を認めたが,併用薬の変更等により消失した.造血器悪性腫瘍患者におけるITCZ予防投与の有用性が示唆された
  • Itraconazole capsules as antifungal prophylaxis for neutropenic patients with hematological malignancies from a single institution
    Tomomi Toubai; Junji Tanaka; Shuichi Ota; Naoko Kato; Shintaro Umehara; Kaoru Kahata; Nobuyasu Toyoshima; Masahiro Asaka; Masahiro Imamura
    Japanese Journal of Antibiotics, 58, 6, 507, 517, 2005年12月, [査読有り]
    日本語, 研究論文(学術雑誌)
  • Successful reduced-intensity stem cell transplantation (RIST) for a patient with malignant lymphoma and an ileostomy
    T Toubai; J Tanaka; S Ota; A Mori; M Ibata; Y Shono; S Mashiko; J Sugita; Y Miura; N Kato; S Umehara; K Kahata; N Toyoshima; M Asaka; M Imamura
    INTERNAL MEDICINE, 44, 5, 476, 479, 2005年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • [TGF-beta signaling and carcinogenesis].
    Kahata K; Asaka M; Miyazono K
    Nihon rinsho. Japanese journal of clinical medicine, 63 Suppl 4, 4, 549, 554, 2005年04月, [招待有り], [筆頭著者], [国内誌]
  • Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection
    M Onozawa; S Hashino; K Izumiyama; K Kahata; M Chuma; A Mori; T Kondo; N Toyoshima; S Ota; S Kobayashi; S Hige; T Toubai; J Tanaka; M Imamura; M Asaka
    TRANSPLANTATION, 79, 5, 616, 619, 2005年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Long-term follow-up of a patient with idiopathic myelofibrosis associated with chromosome 11 and 13 abnormalities
    T Toubai; J Tanaka; T Higa; S Ota; M Ibata; Y Shono; S Mashiko; Y Miura; S Umehara; K Kahata; N Toyoshima; M Morioka; M Asaka; M Kasai; M Imamura
    AMERICAN JOURNAL OF HEMATOLOGY, 78, 1, 67, 70, 2005年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies
    T Toubai; J Tanaka; A Mori; S Hashino; S Kobayashi; S Ota; Y Miura; N Kato; K Kahata; K Izumiyama; M Yonezumi; K Chiba; T Kondo; N Toyoshima; M Asaka; M Imamura
    CLINICAL TRANSPLANTATION, 18, 5, 552, 557, 2004年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Cytolytic activity and regulatory functions of inhibitory NK cell receptor-expressing T cells expanded from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells
    J Tanaka; T Toubai; Y Tsutsumi; Y Miura; N Kato; S Umehara; K Kahata; A Mori; N Toyoshima; S Ota; T Kobayashi; M Kobayashi; M Kasai; M Asaka; M Imamura
    BLOOD, 104, 3, 768, 774, 2004年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study
    S Ota; J Tanaka; K Kahata; T Toubai; K Kondo; A Mori; N Toyoshima; M Musashi; M Asaka; M Imamura
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 79, 4, 390, 393, 2004年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • 非血縁者間同種臍帯血移植後の免疫機能の再構築の検討
    東梅 友美; 三浦 洋子; 田中 淳司; 梅原 伸太郎; 加畑 馨; 太田 秀一; 豊島 經康; 浅香 正博; 今村 雅寛
    日本内科学会雑誌, 93, Suppl., 140, 140, (一社)日本内科学会, 2004年02月
    日本語
  • Regulation of transforming growth factor-beta and bone morphogenetic protein signalling by transcriptional coactivator GCN5
    K Kahata; M Hayashi; M Asaka; U Hellman; H Kitagawa; J Yanagisawa; S Kato; T Imamura; K Miyazono
    GENES TO CELLS, 9, 2, 143, 151, 2004年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • 侵襲性肺アスペルギルス症に対しミカファンギンが奏効した急性リンパ性白血病の1例
    太田 秀一; 田中 淳司; 加畑 馨; 東梅 友美; 豊島 經康; 盛 暁生; 武藏 学; 浅香 正博; 今村 雅寛
    臨床血液, 44, 8, 858, 858, (一社)日本血液学会-東京事務局, 2003年08月
    日本語
  • Platelet recovery in patients with idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori
    S Hashino; A Mori; S Suzuki; K Izumiyama; K Kahata; M Yonezumi; K Chiba; T Kondo; S Ota; N Toyashima; N Kato; J Tanaka; M Imamura; M Asaka
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 77, 2, 188, 191, 2003年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Increased proportion of HLA-class-I-specific natural killer cell receptors (CD94) on peripheral blood mononuclear cells after allogeneic bone marrow transplantation
    J Tanaka; Y Tutumi; L Zhang; A Mori; K Kahata; N Toyoshima; S Ohta; S Kobayashi; S Hashino; M Asaka; M Imamura
    ACTA HAEMATOLOGICA, 105, 2, 89, 91, 2001年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Bone marrow infarction due to acute graft-versus-host disease in an acute lymphoblastic leukemia patient after unrelated bone marrow transplantation
    A Mori; S Hashino; M Imamura; K Kahata; H Kawakami; M Shibata; S Kobayashi; J Tanaka; M Asaka
    BONE MARROW TRANSPLANTATION, 21, 6, 615, 617, 1998年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Bone marrow dysplasia with basophilic cells in a patient with angiocentric lymphoma
    A Mori; S Hashino; M Imamura; K Kahata; H Kawakami; S Kobayashi; J Tanaka; M Musashi; M Asaka
    ACTA HAEMATOLOGICA, 99, 2, 98, 101, 1998年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Inhaled vancomycin-induced allergic reaction in decontamination of respiratory tracts for allogeneic bone marrow transplantation
    K Kahata; S Hashino; M Imamura; A Mori; S Kobayashi; M Asaka
    BONE MARROW TRANSPLANTATION, 20, 11, 1001, 1003, 1997年12月, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌)
  • 骨髄移植時の無菌化薬剤吸入により過敏性肺臓炎をきたしたCMLの1例
    加畑馨; 橋野聡; 河上洋; 柴田美香; 盛暁生; 小林寿美子; 今村雅寛; 浅香正博
    無菌生物, 27, 2, 98-100, 1997年
    日本語
■ その他活動・業績
■ 書籍等出版物
■ 主な担当授業
  • トランスレーショナルリサーチ概論, 2024年, 修士課程, 医学院
  • トランスレーショナルリサーチ概論, 2024年, 博士後期課程, 医学院
  • トランスレーショナルリサーチ概論, 2024年, 学士課程, 医学部
  • 統合・血液学, 2024年, 学士課程, 医学部
■ 共同研究・競争的資金等の研究課題
  • アドリアマイシン心筋症における免疫老化の果たす役割の解明と早期検出法の開発
    科学研究費助成事業
    2021年04月01日 - 2024年03月31日
    石森 直樹; 横田 卓; 加畑 馨
    近年わが国では急速な高齢化が進行してがん患者数は増加し、国民の2人に1人は生涯がんに罹患すると言われている。がんの早期発見や治療法の進歩により、がん患者の生命予後は著しく改善してきたが、再発がん患者では「がん死」に次いで死因第2位に「心血管病」が挙がっており、がん診療での心血管病の制御はきわめて重要な課題となっている。
    アドリアマイシンをはじめとするアントラサイクリン系抗がん剤は、分子標的薬が登場した現代においてもリンパ腫、乳がんおよび肉腫などに対する標準的化学療法薬として重要な位置づけにある。しかし、累積使用量(アドリアマイシン換算)400mg/m2で約5%、700mg/m2では約25%と用量依存的に心筋障害を合併し、時に難治性心不全をきたして死に至る。疫学研究によって累積使用量のほか、年齢や放射線治療歴など心筋障害合併リスク因子が明らかにされているが、化学療法から年余を経て突然心不全を発症し、薬剤性心筋症と診断される例も少なくなく、細心の注意が必要である。
    近年、加齢関連疾患の病態形成においていわゆる老化関連T細胞が出現する「免疫老化」の寄与が注目されている。我々はアドリアマイシン心筋症の発症・進展において「免疫老化」を基盤として慢性炎症が遷延し、心筋症発症に寄与するとの仮説を立てた。本研究の遂行によって、アドリアマイシン心筋症発症リスクのより正確な予測が可能となるばかりでなく、慢性炎症の制御という新たなコンセプトに基づくアドリアマイシン心筋症の予防・治療法の開発に貢献することが期待して本研究を立案した。
    現在、標準的化学療法薬としてアドリアマイシンを用いたレジメで治療された悪性リンパ腫患者の治療フローを確認しながら、アドリアマイシン心筋症に関するレジストリ構築中である。
    日本学術振興会, 基盤研究(C), 北海道大学, 21K08046